Biofarm Valuation

Is BIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIO (RON0.82) is trading above our estimate of fair value (RON0.48)

Significantly Below Fair Value: BIO is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO?

Other financial metrics that can be useful for relative valuation.

BIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA7.7x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does BIO's PE Ratio compare to its peers?

The above table shows the PE ratio for BIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.8x
ATB Antibiotice
13.6xn/aRON1.2b
SCD Zentiva
10.4xn/aRON2.0b
002826 Tibet AIM Pharm
33.2xn/aCN¥1.6b
IMP Imexpharm
18xn/a₫4.6t
BIO Biofarm
10.8xn/aRON810.0m

Price-To-Earnings vs Peers: BIO is good value based on its Price-To-Earnings Ratio (10.8x) compared to the peer average (18.8x).


Price to Earnings Ratio vs Industry

How does BIO's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: BIO is good value based on its Price-To-Earnings Ratio (10.8x) compared to the European Pharmaceuticals industry average (22.2x).


Price to Earnings Ratio vs Fair Ratio

What is BIO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.8x
Fair PE Ration/a

PM vs Fair Ratio: Insufficient data to calculate BIO's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.